zurück Home

Rhabdomyosarkom: Studien, Ergebnisse

Allgemeines

  
VIT-0910 Bei der Behandlung des rezidivierenden Rhabdomyosarkoms verbessert Temozolomid die Behandlung Vincristin und Irinotecan.  (9)
SIOP International Society of Pediatric Oncology
MMT Die SIOP hat eine MMT - Gruppe gebildet (Malignant Mesenchymal Tumor committee). Diese Gruppe hat bedeutende Behandlungsprotokolle entwickelt und evaluiert: MMT 84 Protocol, MMT 89 Protocol.

First Intergroup Rhabdomyosarcoma Study

 Beginn 1972 Patienten mit metastasiertem Rhabdomyosarcoma erzielten innerhalb von 15 Wochen in 50% eine CR und in 25% eine PR.(2)

COG ARST 0431

Quellen

 1.) Sorensen PH, Lynch JC, Qualman SJ, et al:
PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the Children’s Oncology Group.
JCO 20(2002):2672-2679

2.) Maurer HM, Beltangady M, Gehan EA, et al.:
The Intergroup Rhabdomyosarcoma Study-I: A final report.
Cancer 1988;61:209-220

3.) Maurer HM, Gehan EA, Beltangady M, et al.:
The Intergroup Rhabdomyosarcoma Study-II.
Cancer 1993;71:1904-1922

4.) Crist W, Gehan EA, Ragab AH, et al.:
The Third Intergroup Rhabdomyosarcoma Study.
J Clin Oncol 1995;13:610-630

5.) Breneman JC, Lyden E, Pappo AS, et al.:
Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study IV.
J Clin Oncol 2003;21:78-84

6.) Walterhouse DO, Lyden ER, Breitfeld PP, et al.:
Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: A Children ’ s Oncology Group study.
J Clin Oncol 2004;22:1398-1403

7.) Pappo AS, Lyden E, Breitfeld P, et al.:
Children ’ s Oncology Group: Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children ’ s Oncology Group.
J Clin Oncol 2007;25:362-369

8.) Weigel BJ, Lyden E, Anderson JR, et al.:
Intensive multi-agent therapy, including dose-compressed cycles of ifosfamide/etoposide (IE) and vincristine/doxorubicin/cyclophosphamide (VDC), irinotecan and radiation for patients with high-risk rhabdomyosarcoma: A report from the Children ’ s Oncology Group.
J Clin Oncol 2016;34:117-122

9.) Defachelles A-S, et al.:
Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
J Clin Oncol 2021;39:2979-2990
PMID: 34343032


Impressum                         Zuletzt geändert am 31.01.2016 16:27